Acologix

Acologix' leading hard tissue regeneration compound, AC- 100 (Dentonin(R)) is currently under investigation in two Phase II clinical studies in Europe and the United States for the repair of periodontal defects and in dental restorations, respectively. Acologix is also developing AC-200 (Phosphatonin) to treat hyperphosphatemia and its subsequent clinical problems associated with chronic kidney disease. Acologix plans to use most of the funding for the Phase III clinical development of AC-820, its drug candidate for the treatment of uremic pruritus in dialysis patients.

Acologix strives to improve patients' lives by developing and commercializing innovative biopharmaceuticals targeting "osteo-renal" (bone and kidney) diseases. Acologix' substantial expertise in identifying and developing therapeutics with unique mechanisms of action in the osteo-renal field will be a key to solving major kidney and bone health problems. Such conditions include chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. These conditions are present in increasing numbers worldwide and require the development of novel therapeutics.

For more information go to www.acologix. Acologix, a privately held biopharmaceutical company, is developing and commercializing novel biopharmaceuticals targeting osteo-renal indications, including the complications of chronic kidney disease and dialysis, bone and cartilage repair and regeneration, and general dental and oral care. The company's most advanced program, AC-820 (TRK-820) is in Phase 3 and registration stages in the U.S. and Japan, respectively for the treatment of uremic pruritus in dialysis patients. The second program, AC- 100, a new class of hard tissue growth promoting molecule, has been studied in two Phase II clinical studies and demonstrated high safety profile and selective hard tissue formation activities in dental restoration procedures. Further studies have revealed more evidence that AC-100 selectively promotes bone and cartilage repair and regeneration.

Additionally, the Company plans to continue development of its hard tissue regeneration compound, AC-100, and AC-200, a drug candidate aimed at reducing serum phosphate levels associated with chronic kidney disease. HAYWARD, Calif., June 19 /PRNewswire/ -- Acologix, , a privately held biopharmaceutical company, and Toray Industries, of Tokyo, Japan, announced that the companies have entered into a development and license agreement relating to Acologix' AC-200 program in Japan. AC-200, or Phosphatonin, is a recombinant protein in preclinical development for the treatment of hyperphosphatemia, a condition where serum phosphate levels are elevated. Hyperphosphatemia is a common problem for end or advanced-stage renal disease patients that can lead to a variety of serious medical conditions including cardiovascular events and bone disease. NEW YORK (MarketWatch) -- Acologix late Wednesday filed with U.S. regulators to raise up to $115 million in an initial public offering to trade on the Tokyo Stock Exchange Mothers Section.

Acologix is a California-based biopharma firm developing drugs to treat renal diseases, including diseases related to hard tissues, such as bone, teeth and cartilage, as well as the kidney and associated organs. Acologix started life as a consulting business run by current CEO Yoshinari Kumagai, who spent eight years saving money before turning the company into a drug-development firm in 2000. The East Bay Business Times profiled Kumagai here. HAYWARD, Calif., Dec. 20 /PRNewswire/ -- Acologix, , a privately held biopharmaceutical company, announced today that the Company has raised $25.3 million in Series C financing.

Acologix is uniquely focused on these rapidly growing health care problems. In June 2005, Acologix has announced a partnership with Toray Industries, of Japan on the development and commercialization of AC-820 (or TRK-820), an anti-pruritic agent for the treatment of uremic pruritus in dialysis patients. A European Phase III pivotal clinical study is underway. Acologix plans to launch a US Phase III trial in late 2006.

Acologix, a privately held biopharmaceutical company, is developing and commercializing innovative biopharmaceuticals targeting osteo-renal diseases, including chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. Acologix has been partnering with Toray on the development and commercialization of TRK-820 for the treatment of uremic pruritus in dialysis patients. TRK-820 is being studied in a European Phase 3 pivotal clinical trial, and the conduct of a Phase 3 trial is planned in the United States. AC-100 (Dentonin(R)), a novel small peptide with dental, periodontal and orthopedic applications, is currently being studied in two Phase 2 clinical studies, one in dental restoration procedures and another for the repair of periodontal defects. Acologix is also developing AC-200 (Phosphatonin) to treat hyperphosphatemia and subsequent clinical problems associated with chronic kidney disease.

For more information go to www.acologix. Acologix, a privately held biopharmaceutical company, is developing and commercializing novel biopharmaceuticals targeting osteo-renal indications, including the complications of chronic kidney disease and dialysis, bone and cartilage repair and regeneration, and general dental and oral care. The company's most advanced program, AC-820 (TRK-820) is in Phase 3 and registration stages in the U.S. and Japan, respectively for the treatment of uremic pruritus in dialysis patients. The second program, AC- 100, a new class of hard tissue growth promoting molecule, has been studied in two Phase II clinical studies and demonstrated high safety profile and selective hard tissue formation activities in dental restoration procedures. Further studies have revealed more evidence that AC-100 selectively promotes bone and cartilage repair and regeneration.

Acologix' leading hard tissue regeneration compound, AC- 100 (Dentonin(R)) is currently under investigation in two Phase II clinical studies in Europe and the United States for the repair of periodontal defects and in dental restorations, respectively. Acologix is also developing AC-200 (Phosphatonin) to treat hyperphosphatemia and its subsequent clinical problems associated with chronic kidney disease. Acologix plans to use most of the funding for the Phase III clinical development of AC-820, its drug candidate for the treatment of uremic pruritus in dialysis patients.

Additionally, the Company plans to continue development of its hard tissue regeneration compound, AC-100, and AC-200, a drug candidate aimed at reducing serum phosphate levels associated with chronic kidney disease. HAYWARD, Calif., June 19 /PRNewswire/ -- Acologix, , a privately held biopharmaceutical company, and Toray Industries, of Tokyo, Japan, announced that the companies have entered into a development and license agreement relating to Acologix' AC-200 program in Japan. AC-200, or Phosphatonin, is a recombinant protein in preclinical development for the treatment of hyperphosphatemia, a condition where serum phosphate levels are elevated. Hyperphosphatemia is a common problem for end or advanced-stage renal disease patients that can lead to a variety of serious medical conditions including cardiovascular events and bone disease. NEW YORK (MarketWatch) -- Acologix late Wednesday filed with U.S. regulators to raise up to $115 million in an initial public offering to trade on the Tokyo Stock Exchange Mothers Section.

Acologix first filed for an initial offering in August 2006. The company’s lead drug candidate, known as TRK-820, is a drug intended to treat a severe itch known as uremic pruritis that is associated with kidney disease. The drug, which Acologix licensed from Toray Industries in June 2005, is in a late-stage human trial in Europe and scheduled to begin a U.S. test in 2007. Another drug, AC-100, has failed two mid-stage trials for the restoration of teeth and oral bone.

Acologix is also developing AC- 200 (Phosphatonin) to treat hyperphosphatemia and renal osteodystrophy. For more information, go to www.acologix. HAYWARD, CA, USA | November 7, 2008 | Acologix, , a privately held biopharmaceutical company, will present data indicating that its therapeutic product candidate AC-200 improved bone architecture in a rat model of chronic kidney disease. AC-200, an endogenous human protein produced by bone cells, was evaluated in a well accepted rodent model of chronic kidney disease (CKD) in which bone loss is rapid and substantial. The data will be presented by David Rosen, Ph.D on November 8, 2008 at the 41st ASN (American Society of Nephrology) Annual Meeting in Philadelphia, PA.

Total Funding Amount $70M CB Rank (Company) 198,698 Acologix Acologix is a biopharmaceutical company developing therapeutic compounds for the treatment of osteo-renal diseases. Hayward, California, United States Categories Biopharma, Biotechnology, Medical Headquarters Regions San Francisco Bay Area, Silicon Valley, West Coast Founded Date 1992 Founders Yoshinari Kumagai Operating Status Active Funding Status Late Stage Venture Last Funding Type Series C Number of Employees 11-50 IPO Status Private Company Type For Profit Website www.acologix Contact Email [email protected] Phone Number (510)512-7200 Acologix, a biopharmaceutical company, focuses on the identification, development, and commercialization of therapeutic compounds for the treatment of osteo-renal diseases.

Acologix, a privately held biopharmaceutical company, is developing and commercializing innovative biopharmaceuticals targeting osteo-renal diseases, including chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. Acologix has been partnering with Toray on the development and commercialization of TRK-820 for the treatment of uremic pruritus in dialysis patients. TRK-820 is being studied in a European Phase 3 pivotal clinical trial, and the conduct of a Phase 3 trial is planned in the United States. AC-100 (Dentonin(R)), a novel small peptide with dental, periodontal and orthopedic applications, is currently being studied in two Phase 2 clinical studies, one in dental restoration procedures and another for the repair of periodontal defects. Acologix is also developing AC-200 (Phosphatonin) to treat hyperphosphatemia and subsequent clinical problems associated with chronic kidney disease.

Acologix strives to improve patients' lives by developing and commercializing innovative biopharmaceuticals targeting "osteo-renal" (bone and kidney) diseases. Acologix' substantial expertise in identifying and developing therapeutics with unique mechanisms of action in the osteo-renal field will be a key to solving major kidney and bone health problems. Such conditions include chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. These conditions are present in increasing numbers worldwide and require the development of novel therapeutics.

Acologix is a California-based biopharma firm developing drugs to treat renal diseases, including diseases related to hard tissues, such as bone, teeth and cartilage, as well as the kidney and associated organs. Acologix started life as a consulting business run by current CEO Yoshinari Kumagai, who spent eight years saving money before turning the company into a drug-development firm in 2000. The East Bay Business Times profiled Kumagai here. HAYWARD, Calif., Dec. 20 /PRNewswire/ -- Acologix, , a privately held biopharmaceutical company, announced today that the Company has raised $25.3 million in Series C financing.

Acologix first filed for an initial offering in August 2006. The company’s lead drug candidate, known as TRK-820, is a drug intended to treat a severe itch known as uremic pruritis that is associated with kidney disease. The drug, which Acologix licensed from Toray Industries in June 2005, is in a late-stage human trial in Europe and scheduled to begin a U.S. test in 2007. Another drug, AC-100, has failed two mid-stage trials for the restoration of teeth and oral bone.

Acologix strives to improve patients' lives by developing and commercializing innovative biopharmaceuticals targeting "osteo-renal" (bone and kidney) diseases. Acologix' substantial expertise in identifying and developing therapeutics with unique mechanisms of action in the osteo-renal field will be a key to solving major kidney and bone health problems. Such conditions include chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. These conditions are present in increasing numbers worldwide and require the development of novel therapeutics.

Acologix' leading hard tissue regeneration compound, AC- 100 (Dentonin(R)) is currently under investigation in two Phase II clinical studies in Europe and the United States for the repair of periodontal defects and in dental restorations, respectively. Acologix is also developing AC-200 (Phosphatonin) to treat hyperphosphatemia and its subsequent clinical problems associated with chronic kidney disease. Acologix plans to use most of the funding for the Phase III clinical development of AC-820, its drug candidate for the treatment of uremic pruritus in dialysis patients.

For more information go to www.acologix. Acologix, a privately held biopharmaceutical company, is developing and commercializing novel biopharmaceuticals targeting osteo-renal indications, including the complications of chronic kidney disease and dialysis, bone and cartilage repair and regeneration, and general dental and oral care. The company's most advanced program, AC-820 (TRK-820) is in Phase 3 and registration stages in the U.S. and Japan, respectively for the treatment of uremic pruritus in dialysis patients. The second program, AC- 100, a new class of hard tissue growth promoting molecule, has been studied in two Phase II clinical studies and demonstrated high safety profile and selective hard tissue formation activities in dental restoration procedures. Further studies have revealed more evidence that AC-100 selectively promotes bone and cartilage repair and regeneration.

Additionally, the Company plans to continue development of its hard tissue regeneration compound, AC-100, and AC-200, a drug candidate aimed at reducing serum phosphate levels associated with chronic kidney disease. HAYWARD, Calif., June 19 /PRNewswire/ -- Acologix, , a privately held biopharmaceutical company, and Toray Industries, of Tokyo, Japan, announced that the companies have entered into a development and license agreement relating to Acologix' AC-200 program in Japan. AC-200, or Phosphatonin, is a recombinant protein in preclinical development for the treatment of hyperphosphatemia, a condition where serum phosphate levels are elevated. Hyperphosphatemia is a common problem for end or advanced-stage renal disease patients that can lead to a variety of serious medical conditions including cardiovascular events and bone disease. NEW YORK (MarketWatch) -- Acologix late Wednesday filed with U.S. regulators to raise up to $115 million in an initial public offering to trade on the Tokyo Stock Exchange Mothers Section.

Total Funding Amount $70M CB Rank (Company) 198,698 Acologix Acologix is a biopharmaceutical company developing therapeutic compounds for the treatment of osteo-renal diseases. Hayward, California, United States Categories Biopharma, Biotechnology, Medical Headquarters Regions San Francisco Bay Area, Silicon Valley, West Coast Founded Date 1992 Founders Yoshinari Kumagai Operating Status Active Funding Status Late Stage Venture Last Funding Type Series C Number of Employees 11-50 IPO Status Private Company Type For Profit Website www.acologix Contact Email [email protected] Phone Number (510)512-7200 Acologix, a biopharmaceutical company, focuses on the identification, development, and commercialization of therapeutic compounds for the treatment of osteo-renal diseases.

Acologix is also developing AC- 200 (Phosphatonin) to treat hyperphosphatemia and renal osteodystrophy. For more information, go to www.acologix. HAYWARD, CA, USA | November 7, 2008 | Acologix, , a privately held biopharmaceutical company, will present data indicating that its therapeutic product candidate AC-200 improved bone architecture in a rat model of chronic kidney disease. AC-200, an endogenous human protein produced by bone cells, was evaluated in a well accepted rodent model of chronic kidney disease (CKD) in which bone loss is rapid and substantial. The data will be presented by David Rosen, Ph.D on November 8, 2008 at the 41st ASN (American Society of Nephrology) Annual Meeting in Philadelphia, PA.

Acologix is uniquely focused on these rapidly growing health care problems. In June 2005, Acologix has announced a partnership with Toray Industries, of Japan on the development and commercialization of AC-820 (or TRK-820), an anti-pruritic agent for the treatment of uremic pruritus in dialysis patients. A European Phase III pivotal clinical study is underway. Acologix plans to launch a US Phase III trial in late 2006.

Acologix is a California-based biopharma firm developing drugs to treat renal diseases, including diseases related to hard tissues, such as bone, teeth and cartilage, as well as the kidney and associated organs. Acologix started life as a consulting business run by current CEO Yoshinari Kumagai, who spent eight years saving money before turning the company into a drug-development firm in 2000. The East Bay Business Times profiled Kumagai here. HAYWARD, Calif., Dec. 20 /PRNewswire/ -- Acologix, , a privately held biopharmaceutical company, announced today that the Company has raised $25.3 million in Series C financing.

Acologix, a privately held biopharmaceutical company, is developing and commercializing innovative biopharmaceuticals targeting osteo-renal diseases, including chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. Acologix has been partnering with Toray on the development and commercialization of TRK-820 for the treatment of uremic pruritus in dialysis patients. TRK-820 is being studied in a European Phase 3 pivotal clinical trial, and the conduct of a Phase 3 trial is planned in the United States. AC-100 (Dentonin(R)), a novel small peptide with dental, periodontal and orthopedic applications, is currently being studied in two Phase 2 clinical studies, one in dental restoration procedures and another for the repair of periodontal defects. Acologix is also developing AC-200 (Phosphatonin) to treat hyperphosphatemia and subsequent clinical problems associated with chronic kidney disease.

Acologix first filed for an initial offering in August 2006. The company’s lead drug candidate, known as TRK-820, is a drug intended to treat a severe itch known as uremic pruritis that is associated with kidney disease. The drug, which Acologix licensed from Toray Industries in June 2005, is in a late-stage human trial in Europe and scheduled to begin a U.S. test in 2007. Another drug, AC-100, has failed two mid-stage trials for the restoration of teeth and oral bone.

Total Funding Amount $70M CB Rank (Company) 198,698 Acologix Acologix is a biopharmaceutical company developing therapeutic compounds for the treatment of osteo-renal diseases. Hayward, California, United States Categories Biopharma, Biotechnology, Medical Headquarters Regions San Francisco Bay Area, Silicon Valley, West Coast Founded Date 1992 Founders Yoshinari Kumagai Operating Status Active Funding Status Late Stage Venture Last Funding Type Series C Number of Employees 11-50 IPO Status Private Company Type For Profit Website www.acologix Contact Email [email protected] Phone Number (510)512-7200 Acologix, a biopharmaceutical company, focuses on the identification, development, and commercialization of therapeutic compounds for the treatment of osteo-renal diseases.

Acologix is uniquely focused on these rapidly growing health care problems. In June 2005, Acologix has announced a partnership with Toray Industries, of Japan on the development and commercialization of AC-820 (or TRK-820), an anti-pruritic agent for the treatment of uremic pruritus in dialysis patients. A European Phase III pivotal clinical study is underway. Acologix plans to launch a US Phase III trial in late 2006.

Acologix' leading hard tissue regeneration compound, AC- 100 (Dentonin(R)) is currently under investigation in two Phase II clinical studies in Europe and the United States for the repair of periodontal defects and in dental restorations, respectively. Acologix is also developing AC-200 (Phosphatonin) to treat hyperphosphatemia and its subsequent clinical problems associated with chronic kidney disease. Acologix plans to use most of the funding for the Phase III clinical development of AC-820, its drug candidate for the treatment of uremic pruritus in dialysis patients.

Additionally, the Company plans to continue development of its hard tissue regeneration compound, AC-100, and AC-200, a drug candidate aimed at reducing serum phosphate levels associated with chronic kidney disease. HAYWARD, Calif., June 19 /PRNewswire/ -- Acologix, , a privately held biopharmaceutical company, and Toray Industries, of Tokyo, Japan, announced that the companies have entered into a development and license agreement relating to Acologix' AC-200 program in Japan. AC-200, or Phosphatonin, is a recombinant protein in preclinical development for the treatment of hyperphosphatemia, a condition where serum phosphate levels are elevated. Hyperphosphatemia is a common problem for end or advanced-stage renal disease patients that can lead to a variety of serious medical conditions including cardiovascular events and bone disease. NEW YORK (MarketWatch) -- Acologix late Wednesday filed with U.S. regulators to raise up to $115 million in an initial public offering to trade on the Tokyo Stock Exchange Mothers Section.

Acologix is also developing AC- 200 (Phosphatonin) to treat hyperphosphatemia and renal osteodystrophy. For more information, go to www.acologix. HAYWARD, CA, USA | November 7, 2008 | Acologix, , a privately held biopharmaceutical company, will present data indicating that its therapeutic product candidate AC-200 improved bone architecture in a rat model of chronic kidney disease. AC-200, an endogenous human protein produced by bone cells, was evaluated in a well accepted rodent model of chronic kidney disease (CKD) in which bone loss is rapid and substantial. The data will be presented by David Rosen, Ph.D on November 8, 2008 at the 41st ASN (American Society of Nephrology) Annual Meeting in Philadelphia, PA.

Acologix strives to improve patients' lives by developing and commercializing innovative biopharmaceuticals targeting "osteo-renal" (bone and kidney) diseases. Acologix' substantial expertise in identifying and developing therapeutics with unique mechanisms of action in the osteo-renal field will be a key to solving major kidney and bone health problems. Such conditions include chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. These conditions are present in increasing numbers worldwide and require the development of novel therapeutics.

For more information go to www.acologix. Acologix, a privately held biopharmaceutical company, is developing and commercializing novel biopharmaceuticals targeting osteo-renal indications, including the complications of chronic kidney disease and dialysis, bone and cartilage repair and regeneration, and general dental and oral care. The company's most advanced program, AC-820 (TRK-820) is in Phase 3 and registration stages in the U.S. and Japan, respectively for the treatment of uremic pruritus in dialysis patients. The second program, AC- 100, a new class of hard tissue growth promoting molecule, has been studied in two Phase II clinical studies and demonstrated high safety profile and selective hard tissue formation activities in dental restoration procedures. Further studies have revealed more evidence that AC-100 selectively promotes bone and cartilage repair and regeneration.